Estimated read time: Less than a minute
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.
PHILADELPHIA (AFX) - Women with postmenopausal osteoporosis taking once-monthly Boniva were approximately 25 pct more likely to stay on therapy than women taking the once-weekly medications alendronate or risedronate, Roche Holdings AG and GlaxoSmithKline, which co-market the drug outside Japan, said.
The drugs companies were citing six-month results of ongoing studies, presented to the annual meeting of the American Society for Bone and Mineral Research.
newsdesk@afxnews.com vs COPYRIGHT Copyright AFX News Limited 2005. All rights reserved. The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News. AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
Copyright 2006 AFX News Limited. All Rights Reserved.
